Life sciences companies are making rapid strides toward succeeding in a patient-centric world and a strong divestment strategy is key.
Divestments will play a vital part in rebalancing life sciences’ portfolios
How can you use dealmaking today to capture value from data tomorrow?
Three critical questions life sciences CFOs need to answer on capital allocation
How Life Sciences 4.0 is fusing the digital and biological worlds
When the human body is the biggest data platform, who will capture value?
Achieve sustainable success in the new health-outcomes-driven ecosystem.
Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.
Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.
EY works with companies across the biotechnology, pharmaceutical and medical technology fields to harness this disruption by forming the right alliances, better allocating resources and building trust with customers.
How EY can help:
- Delivering a commercial edge in life sciences
- Outcomes-based payment models
- Intelligent automation in life sciences